Quince Therapeutics (QNCX) restores bid compliance but still below $50M MVLS
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Quince Therapeutics, Inc. reports that Nasdaq has informed the company it has regained compliance with the Nasdaq Global Select Market minimum bid price requirement under Listing Rule 5450(a)(1). The company’s common stock closed at $1.00 or more for 10 consecutive business days from April 13 through April 24, 2026.
The company remains out of compliance with Nasdaq’s market value of listed securities requirement under Listing Rule 5450(b)(2)(A), which requires at least $50,000,000. Quince has until September 14, 2026 to regain compliance with this MVLS requirement, and there is no assurance it will do so or maintain compliance with other listing standards.
Positive
- None.
Negative
- None.
Insights
Quince restores Nasdaq bid-price compliance but still faces MVLS hurdle.
Quince Therapeutics has cleared one key Nasdaq standard: its stock traded at or above $1.00 for 10 consecutive business days, restoring compliance with Listing Rule 5450(a)(1). This removes the immediate risk tied to the minimum bid price test.
The remaining issue is Nasdaq’s market value of listed securities requirement of at least $50,000,000 under Listing Rule 5450(b)(2)(A). Quince has until September 14, 2026 to meet this, and the company explicitly notes there is no assurance it will regain or maintain full listing compliance. The overall impact is mixed: near-term relief on bid price, but continued listing risk tied to MVLS.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Minimum bid price threshold: $1.00 per share
Consecutive days at or above $1.00: 10 business days
MVLS requirement: $50,000,000
+2 more
5 metrics
Minimum bid price threshold
$1.00 per share
Nasdaq Listing Rule 5450(a)(1) requirement
Consecutive days at or above $1.00
10 business days
April 13–24, 2026 closing bid prices
MVLS requirement
$50,000,000
Nasdaq Listing Rule 5450(b)(2)(A) threshold
Initial MVLS deficiency period
30 consecutive business days
Market value of listed securities below $50,000,000
Compliance deadline for MVLS
September 14, 2026
End of 180 calendar day cure period
Key Terms
minimum bid price requirement, market value of listed securities, Nasdaq Global Select Market, Listing Rule 5450(a)(1), +1 more
5 terms
minimum bid price requirement financial
"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
market value of listed securities financial
"the Company’s market value of listed securities (“MVLS”) for the last 30 consecutive business days was less than the $50,000,000 required"
The market value of listed securities is the total worth of stocks, bonds and other tradable instruments quoted on an exchange, measured using the prices investors are willing to pay right now. It’s calculated by multiplying each security’s current market price by the number of units outstanding and adding those amounts together, like totaling the value of every item in a store at today’s prices. Investors watch this because it shows the size, liquidity and overall health of the market or a company’s publicly traded portion, and it influences index weights, fund allocations and perceived risk.
Nasdaq Global Select Market financial
"required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(b)(2)(A)"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Listing Rule 5450(a)(1) regulatory
"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1)"
Listing Rule 5450(b)(2)(A) regulatory
"required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”)"
FAQ
What Nasdaq compliance update did Quince Therapeutics (QNCX) disclose?
Quince Therapeutics disclosed it regained compliance with Nasdaq’s minimum bid price rule, as its stock closed at $1.00 or more for 10 consecutive business days. However, it is still not in compliance with Nasdaq’s market value of listed securities requirement.
How did Quince Therapeutics regain Nasdaq minimum bid price compliance?
Quince regained compliance because its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days, from April 13 through April 24, 2026. Nasdaq’s Listing Qualifications staff confirmed this satisfied Listing Rule 5450(a)(1).
Which Nasdaq listing requirement does Quince Therapeutics (QNCX) still fail to meet?
Quince remains out of compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires a market value of listed securities of at least $50,000,000. The company previously received an MVLS notice reflecting that its market value had been below this threshold for 30 consecutive business days.
How long does Quince Therapeutics have to fix its Nasdaq MVLS deficiency?
Quince Therapeutics has 180 calendar days, until September 14, 2026, to regain compliance with Nasdaq’s market value of listed securities requirement. If it does not meet the $50,000,000 MVLS threshold by then, additional Nasdaq actions regarding its listing status could follow.
Does regaining the minimum bid price guarantee Quince Therapeutics stays on Nasdaq?
Regaining the minimum bid price requirement closes that specific issue but does not guarantee continued listing. Quince still must satisfy Nasdaq’s $50,000,000 market value of listed securities requirement and acknowledges there is no assurance of regaining or maintaining full listing compliance.
What stock market is Quince Therapeutics’ common stock listed on?
Quince Therapeutics’ common stock is listed on the Nasdaq Global Select Market under the trading symbol QNCX. The company’s listing is subject to meeting Nasdaq’s continued listing standards, including minimum bid price and market value of listed securities requirements.